How much is Eli Lilly paying for AtaiBeckley?

Eli Lilly agreed to pay $6.75 per share in cash upfront, valuing the deal at approximately $2.8 billion. Shareholders may also receive a contingent value right worth up to $2.50 per share, roughly $1 billion more, tied to future development and regulatory milestones. The combined deal value could reach up to $3.8 billion, or about $9.25 per share, if all milestones are met.

What is AtaiBeckley's lead drug, BPL-003?

BPL-003 is an intranasal formulation of mebufotenin benzoate, a synthetic form of 5-MeO-DMT, being developed for treatment-resistant depression. In a Phase 2b trial it showed statistically significant improvement starting on day two, with effects maintained through day 57, and it has since advanced into Phase III development.

When is the Eli Lilly and AtaiBeckley deal expected to close?

The companies expect the transaction to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders and customary regulatory clearances.

Why do some analysts think the AtaiBeckley deal undervalues the company?

AtaiBeckley has a cash runway extending through 2029 and is not in financial distress, which raises the question of why it would accept a full buyout at a discount rather than pursuing alternative capital sources, such as a follow-on equity raise, to fund its earlier-stage pipeline.

Eli Lilly Just Bought AtaiBeckley for $3.8 Billion. The Market's Cheering. We're Not So Sure.

Rebellionaire Staff
4 minutes ago
3 min read

Big Pharma doesn't chase fringe science. Not unless the data forces its hand.

That's what makes this week's news notable. On July 16, 2026, Eli Lilly (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley Inc. (Nasdaq: ATAI) — the psychedelic-medicine company formed less than a year ago through the merger of Germany's atai Life Sciences and the UK's Beckley Psytech. It's Lilly's first move into psychedelics, and it comes on the heels of a broader acquisition spree the company has run this year, using its weight-loss-drug windfall to buy its way into new areas of neuroscience and beyond.

Wall Street's initial reaction was enthusiastic. AtaiBeckley shares jumped more than 30% on the news. Analysts framed it as validation — proof that psychedelic medicine has graduated from fringe research to mainstream pharma strategy.

We're not disputing the science. We're disputing the price.

What Lilly Is Actually Buying

AtaiBeckley's lead asset is BPL-003, an intranasal formulation of mebufotenin benzoate — a synthetic form of 5-MeO-DMT — being developed for treatment-resistant depression (TRD). TRD affects patients who haven't responded to standard treatments, and it's a large, underserved population. In a Phase 2b trial, BPL-003 produced statistically significant improvement starting as early as day two, with effects holding through day 57. The drug has since advanced into Phase III development.

Beyond BPL-003, the pipeline includes VLS-01, a buccal film formulation of DMT for major depressive disorder, and EMP-01, an (R)-MDMA compound for social anxiety disorder — plus a broader discovery pipeline of next-generation neuroplastogens.

Under the terms of the deal:

Lilly will pay $6.75 per share in cash upfront, valuing the deal at roughly $2.8 billion.
Shareholders can also receive a contingent value right (CVR) worth up to $2.50 per share — roughly another $1 billion — tied to future development and regulatory milestones.
Combined, the deal could be worth up to $3.8 billion, or about $9.25 per share, if every milestone is hit.
The deal is expected to close in Q3 2026, pending shareholder and regulatory approval.

Where the Skepticism Comes In

Here's the part that doesn't sit well with us: the CVR money isn't guaranteed, and it isn't fast. It's collected — if at all — over several years, contingent on clinical and regulatory outcomes that haven't happened yet. Strip that out, and shareholders are being asked to accept $6.75 per share in cash, certain and immediate, for a company that isn't in financial distress.

AtaiBeckley's cash runway extends through 2029. This isn't a company that needed to be rescued. It's a company with a Phase III asset showing durable efficacy against an existing standard of care, in a total addressable market that runs into the tens of billions across depression and PTSD. Companies with that profile don't typically need to sell at a discount — they need capital to keep advancing earlier-stage assets like VLS-01 and EMP-01, and given how well other psychedelic developers (Compass Pathways, for one) have been received in the public markets recently, a follow-on equity raise looks like a very plausible alternative to a full buyout.

That's the pattern we watch for: a company with real clinical momentum and no urgent liquidity need, agreeing to a price that a straight read of its pipeline suggests undervalues it. When that pattern shows up, the question worth asking isn't "is this a good deal for Lilly" — it obviously is — it's "is this the best outcome available to the people who backed this company through the hard, unproven years."

Read the Full Case

Halter Ferguson Financial has published an open letter to the AtaiBeckley Board of Directors laying out the full argument in detail — including a direct comparison to Wall Street's own price targets on the stock. If you want the complete breakdown, read it here: An Open Letter to the AtaiBeckley Board of Directors.

This post reflects Rebellionaire's independent analysis of publicly available deal terms and is not investment advice. It is not a recommendation to buy, sell, hold, or vote any security, and it is not a solicitation. AtaiBeckley shareholders should consult the merger proxy materials and their own financial and legal advisors before making any decision related to the proposed transaction.